- This article was considered for deletion at Wikipedia on May 2 2014. This is a backup of Wikipedia:Antonio_Giordano. All of its AfDs can be found at Wikipedia:Special:PrefixIndex/Wikipedia:Articles_for_deletion/Antonio_Giordano, the first at Wikipedia:Wikipedia:Articles_for_deletion/Antonio_Giordano.
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)(Learn how and when to remove this template message)
Antonio Giordano (born in Naples, Italy on October 11, 1962) is an Italian-American pathologist and geneticist, he identified and cloned Rb2/p130, a tumor suppressor gene. Giordano is the President and Founder of the Sbarro Health Research Organization, Inc, which conducts research to diagnose, treat and cure cancer, cardiovascular disease, diabetes and other chronic illnesses. He is also the Founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine and the Center for Biotechnology at Temple's College of Science & Technology. He is a founder and Chairman of the Scientific Advisory Board of the Human Health Foundation Onlus (HHF), an Italian charity for basic medical research supported by the Banca Popolare di Spoleto, located in Spoleto, Italy. He also serves as President of the Scientific Advisory Board of the Centro di Ricerche Oncologiche di Mercogliano (CROM), Mercogliano, Italy, which is affiliated with The National Cancer Institute of Naples.
Biography[edit | hide all | hide | edit source]
Giordano was born in Naples, Italy, on October 11, 1962. He is the son of Giovan Giacomo Giordano, an anatomical pathologist , and Maria Teresa Sgambati. Giordano received his medical degree from the University of Naples, Italy, and his doctorate in Pathology from the University of Trieste Medical School. He was a post-doctoral fellow in the Department of Microbiology and Immunology at the New York Medical College in Valhalla, New York and at Cold Spring Harbor Laboratory (CHSL) in Cold Spring, New York.
Discoveries[edit | hide | edit source]
At 26, while a post-doctoral fellow at Cold Spring Harbor Laboratory in New York, Giordano made contributions to the field of cancer research. His work led to the recognition that an identical protein species occurs in complexes with both a virus and with the cell cycle regulatory kinase cdc2. Later, this protein species was identified as protein cyclin A, a substance that regulates growth in the cell cycle.
Giordano went on to discover Rb2/p130 in the early 1990s while serving as a member of Temple's School of Medicine faculty and as a researcher at the Fels Institute for Cancer Research and Molecular Biology. Since that time, Giordano and SHRO researchers have established links between Rb2/p130 and its expression with the regression of cancer in the lungs, the aggression of cancer in the liver and ovaries, the effectiveness of drug therapies against breast cancer, and its role as a potential prognosticator of prostate cancer.
Giordano discovered Cdk9 and Cdk10, a genetic substances that must be activated to guarantee proper progression through the cell cycle. Recent research has focused on the role of Cdk9-55 in helping to regenerate muscle tissue in cases of muscle wasting from disease or aging.
In 2004, Giordano discovered [Novel Structure Proteins (NSPs)], a new family of structural proteins with a possible role in nuclear dynamics during cell division. One form of the gene, the isoform [NSP5a3a], is highly expressed in some tumor cell lines and could be very useful as a tumor marker. Isoforms from NSPs could be involved in apoptosis or programmed cell death. Giordano played a role in studying the cyclin-dependent-kinase inhibitor p27 which serves as the prognostic factor in cancer patients.
Foundations[edit | hide | edit source]
In 1993, Giordano founded the Sbarro Institute with a donation from Mario Sbarro, founder of the Sbarro restaurant chain, following Giordano’s discovery of the tumor suppressor gene pRb2/p130. Initially named the Sbarro Institute, the research center was located at Thomas Jefferson University, where Giordano was a professor. When Giordano moved to Temple University in 2002, he and twenty fellow scientists forged a new, three-year alliance with Temple University in Philadelphia, Pennsylvania. The original Sbarro Institute was renamed the Sbarro Health Research Organization, Inc., which includes the Sbarro Institute for Cancer Research and Molecular Medicine and funds a program in the University of Siena.
In 2006, Giordano founded the Human Health Foundation, a charitable organization raising funds to support biomedical research and health education in Italy. Giordano is a founding member of the International Hologenomics Society.
Patents and publications[edit | hide | edit source]
His work is funded by National Institutes of Health (NIH) grants, the Department of Defense, and the Commonwealth of Pennsylvania as well as individual and program project grants from SHRO. Since 1992, Giordano has been awarded different patents and he has published over 400 papers on his work in the fields of cell cycle, gene therapy, the genetics of cancer, and the epidemiology of cancer. He serves on the editorial boards of a number of professional journals.
Giordano serves as the series editor for textbooks on pathology. He is co-editor of an oncologytextbook. He has also co-edited Diagnostica Molecolare nella Medicina di Laboratorio. Vol IX, Cell Cycle Regulation and Differentiation in Cardiovascular and Neural Systems, and Breast Cancer in the Post-Genomic Era.
Awards[edit | hide | edit source]
In November 2012, Giordano was awarded Premio Grande Ippocrate or Hippocrates Grand Prize for exceptional research, international collaboration and communicating scientific discoveries to the general public. In March 2011, Giordano was one of seven distinguished Italian Americans to be named to the board of the National Italian American Foundation. Giordano has been named a Knight of the Republic of Italy for outstanding achievements in cancer research. In October 2010, he was named a Commendatore, or Knight Commander, by the President of the Republic of Italy. In December 2010, he was named as an Honorary Professor of the Autonomous University of Santo Domingo in the Dominican Republic for his achievements in research and the development of biomedicine. He has been honored by The National Association of Italian American Women for his achievements in the fields of cell cycle, gene therapy, and the genetics of cancer. In 2010, he was appointed by the executive committees of the Federazione Pugilistica Italiana and the International Boxing Association to be a member of their medical commissions. In June 2009, he received the Premio Casentino in Medicine, from the Center Fonte Aretusa in the city of Poppi (Tuscany) and the GOIM award, Maestri dell`Oncologia (Master of Oncology) in Catania (Sicily). The GOIM (Oncology Group of South Italy) is a non-profit association founded in 1985 which aims to develop and support scientific research in southern Italy and one of the largest oncology networks for clinical trial centers.In September 2009, Giordano received the Philip Mazzei "The Bridge" Award from The American University of Rome for his scientific and economic contributions to the United States and Italy. He is a 'Chiara fama' Professor in the Department of Human Pathology & Oncology at the University of Siena, in Siena, Italy.
References[edit | hide | edit source]
- Mayol X, Grana X, Baldi A, Sang N, Hu Q, Giordano A (September 1993). "Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain". Oncogene 8 (9): 2561–6. PMID 8361765
- Baldi A, Boccia V, Claudio PP, De Luca A, Giordano A (July 1996). "Genomic structure of the human retinoblastoma-related Rb2/p130 gene". P.N.A.S. 93(10):4629-32. PMID 8643454
- Yeung RS, Bell DW, Testa JR, Mayol X, Baldi A, Graña X, Klinga-Levan K, Knudson AG, Giordano A (December 1993). "The retinoblastoma-related gene, RB2, maps to human chromosome 16q12 and rat chromosome 19". Oncogene 8(12):3465-8. PMID 8361765
- Claudio PP, Howard CM, Baldi A, De Luca A, Fu Y, Condorelli G, Sun Y, Colburn N, Calabretta B, Giordano A. (November 1994) "p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107". Cancer Res. 54(21):5556-60. PMID 7923196
- Giordano A, Whyte P, Harlow E, Franza BR Jr, Beach D, Draetta G. (September 1989). "A 60 kd cdc2-associated polypeptide complexes with the E1A proteins in adenovirus-infected cells". Cell 8;58(5):981-90. PMID 2570639
- http://academic.research.microsoft.com/Search?query=Antonio Giordano year>=1991&SearchDomain=6
[edit | hide | edit source]
- Temple University
- University of Siena
- Thomas Jefferson University
- Banca Popolare di Spoleto (in Italian)
Copyright (c) 2007 IRush30. Permission is granted to copy, distribute and/or modify this document under the terms of the GNU Free Documentation License, Version 1.2 or any later version published by the Free Software Foundation; with no Invariant Sections, no Front-Cover Texts, and no Back-Cover Texts. A copy of the license is included in the section entitled "GNU Free Documentation License".
Lua error in Module:Authority_control at line 927: attempt to index field 'wikibase' (a nil value).